Please login (Members) to view content or
(Nonmembers) this article.
0

No votes yet

Online Exclusive Article

The Relationship of Chemotherapy-Induced Nausea to the Frequency of Pericardium 6 Digital Acupressure

Jiyeon Lee
Suzanne Dibble
Marylin Dodd
Donald Abrams
Beverly Burns
ONF 2010, 37(6), E419-E425 DOI: 10.1188/10.ONF.E419-E425

Purpose/Objectives: To explain the relationship between the intensity of chemotherapy-induced nausea (CIN) and the frequency of pericardium 6 (P6) digital acupressure.

Design: Secondary data analysis of a multicenter, longitudinal, randomized, clinical trial.

Setting: Nine community clinical oncology programs and six independent sites in the United States.

Sample: 53 patients with breast cancer who received moderate to highly emetogenic chemotherapy and applied P6 digital acupressure in addition to antiemetics to control CIN.

Methods: A daily log measuring nausea intensity and the frequency of acupressure for 11 days after the administration of chemotherapy. Hierarchical generalized linear modeling procedure (multilevel negative binomial regression) was used for analyzing the data.

Main Research Variables: Nausea intensity and acupressure frequency.

Findings: Participants used acupressure an average of two times per day (SD = 1.84, range 0-10). Women who used acupressure more frequently after the peak of nausea (on day 4) were predicted to have a 0.97-point higher nausea intensity in the acute phase than women who used acupressure less frequently, controlling for the effects of other variables in the model (incidence rate ratio = 1.52, p < 0.01).

Conclusions: Patients with breast cancer whose nausea intensity started higher from the acute phase continued to experience higher symptom intensity during the 11 days after chemotherapy administration and required more frequent acupressure even after the peak of nausea.

Implications for Nursing: Careful assessment and management of acute CIN with continuous monitoring and care of CIN in the delayed phase are important nursing issues in caring for patients receiving chemotherapy.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or